실시간
CellProteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte functionCellDifferential inhibition of <em>Morbillivirus</em> and <em>Henipavirus</em> polymerases by ERDRP-0519 and structure-guided inhibitor optimizationEndpoints NewsAvalyn's upsized IPO; Alector ends another study in GSK partnershipEndpoints NewsAnalysts focus on three programs in big year for Bristol MyersBioPharma DiveLilly posts another ‘blowout quarter’ as focus turns to Foundayo launchEndpoints NewsXTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue riseLonza NewsHigh-throughput chromatography in bioprocess analytics - News-MedicalFierceBiotechIndivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2FierceBiotechBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecificEndpoints NewsWhat we heard at a health tech conference in Boston10x Genomics News10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo FinanceBioWorldHoliday notice
BioWorld 2026년 4월 30일

MFDS clears Curocell’s anbal-cel as first homegrown CAR T therapy

MFDS clears Curocell’s anbal-cel as first homegrown CAR T therapy

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.